Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA – Research Report),
BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended
82 Biggest Movers From Yesterday
08:30am, Wednesday, 29'th Apr 2020
Gainers
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares climbed 69.4% to close at $19.50 on Tuesday after the company presented positive preclinical and initial clinical data...
SAN CARLOS, Calif., April 28, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
12:00am, Tuesday, 28'th Apr 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
BioCardia announces litigation financing for Boston Scientific case BCDA;BSX
12:20pm, Tuesday, 14'th Apr 2020
BioCardia announces litigation financing for Boston Scientific case BCDA BSX
BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia Inc.
12:00pm, Tuesday, 14'th Apr 2020
BioCardia®, Inc. (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing wh
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
06:03pm, Thursday, 09'th Apr 2020
SAN CARLOS, Calif., April 09, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
BioCardia (OTCMKTS:BCDA) Rating Reiterated by Maxim Group
08:30am, Sunday, 05'th Apr 2020
Maxim Group reissued their buy rating on shares of BioCardia (OTCMKTS:BCDA) in a research note issued to investors on Wednesday, AnalystRatings.com reports. Maxim Group currently has a $9.00 target pr
Seasoned Biotech Financial Executive, Jay M. Moyes, Joins Sera Prognostics
12:00pm, Thursday, 02'nd Apr 2020
Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes a
BioCardia (BCDA) Receives a Buy from Maxim Group
05:20pm, Wednesday, 01'st Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
BioCardia (BCDA) Receives a Buy from Maxim Group
05:20pm, Wednesday, 01'st Apr 2020
In a report released today,
Jason McCarthy
from Maxim Group assigned a
Buy
rating to BioCardia (
BCDA
–
Research Report
), with a price target of
$9.00
. The company’s shares closed last Wednesday
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
12:00pm, Tuesday, 31'st Mar 2020
BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has complet
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
04:10pm, Sunday, 29'th Mar 2020
After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate
Should You Take Comfort From Insider Transactions At BioCardia, Inc. (NASDAQ:BCDA)?
12:58pm, Sunday, 29'th Mar 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
